A Study of Olaratumab (IMC-3G3) in Prostate Cancer

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a study evaluating the safety and efficacy of the monoclonal antibody olaratumab plus mitoxantrone plus prednisone compared to mitoxantrone plus prednisone in metastatic castration-refractory prostate cancer following disease progression or intolerance on docetaxel-based chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Mitoxantrone; Olaratumab; Prednisone

Criteria

Inclusion Criteria:

• histologically-confirmed adenocarcinoma of the prostate

• radiographic evidence of metastatic prostate cancer (Stage M1 or D2)

• has prostate cancer unresponsive or refractory to medical or surgical castration with a serum testosterone level of <50 nanograms per milliliter (ng/mL)

• has had disease progression or intolerance on docetaxel-based therapy

• prostate-specific antigen (PSA) ≥10 ng/mL

• all clinically significant toxic effects of prior surgery, radiotherapy, chemotherapy or hormonal therapy have resolved to ≤Grade 1, based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.02

• participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

• adequate hematologic function

• adequate hepatic function

• adequate renal function

• urinary protein is ≤1 on dipstick or routine analysis

• life expectancy of more than 3 months

• fertile man with partners that are women of childbearing potential must use an adequate method of contraception during the study

• signed Informed Consent Document

Exclusion Criteria:

• concurrent active malignancy other than adequately treated nonmelanomatous skin cancer or other noninvasive or in situ neoplasms

• The participant has received more than 1 prior cytotoxic chemotherapy regimen for metastatic disease

• prior therapy with mitoxantrone for advanced prostate cancer

• The participant has a history of symptomatic congestive heart failure or has a pre study echocardiogram or multigated acquisition scan with left ventricular ejection fraction that is ≥10% below the lower limit of normal institutional range

• history of prior treatment with other agents that directly inhibit platelet-derived growth factor (PDGF) or platelet-derived growth factor receptors (PDGFR)

• known allergy to any of the treatment components: olaratumab, mitoxantrone, and/or prednisone

• radiotherapy within 21 days prior to first dose of olaratumab

• any investigational therapy within 30 days of randomization

• is receiving corticosteroids at a dose >5 mg prednisone PO BID or equivalent

• received prior strontium-89, rhenium-186, rhenium-188, or samarium-153 radionucleotide therapy and has either ongoing evidence of bone marrow dysfunction or poorly controlled bone pain

• has any ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, psychiatric illness, active bleeding or pathological condition that carries a high risk of bleeding, or any other serious uncontrolled medical disorders

• known or suspected brain or leptomeningeal metastases

• known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness